Physician profile
Mari E Parker
NPI 1093066284
$5,282.80
in general payments reported to CMS, 2019-2025
43 companies · $999 in 2025
The $999 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $681 · 2022: $827 · 2023: $1,077 · 2024: $1,700 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,775.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $739.30 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Astellas Pharma US INC | $526.75 | 2021-2025 | Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $478.77 | 2021-2025 | Erleada, Akeega |
| Sumitomo Pharma America, INC. | $361.88 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $323.71 | 2022-2025 | |
| Axonics, INC. | $290.39 | 2022-2023 | Axonics |
| Urovant Sciences INC | $257.15 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $242.83 | 2023-2024 | Caplyta |
| Abbvie INC. | $223.19 | 2021-2024 | |
| Tolmar, INC. | $160.88 | 2023-2025 | Eligard, Jatenzo |
| Bayer Healthcare Pharmaceuticals INC. | $125.10 | 2021-2025 | |
| Accord Healthcare, INC. | $122.77 | 2023-2024 | |
| Novo Nordisk INC | $121.74 | 2024 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $114.86 | 2024 | Airsupra |
| Tolmar Pharmaceuticals, INC. | $96.69 | 2021-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mari Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.